Blastomycosis of the prostate: case report.

R. Bunge,W. Harness

DOI: https://doi.org/10.1016/S0022-5347(17)74335-2

1951-08-01

Abstract:

What problem does this paper attempt to address?

Research Progress on Disease Models and Gene Therapy of Duchenne Muscular Dystrophy

Tongyu Li,Ping Liang

DOI: https://doi.org/10.3785/j.issn.1008-9292.2016.11.15

2016-01-01

Abstract:Duchenne muscular dystrophy ( DMD ) is an X-linked, recessive and lethal genetic disease, which usually caused by gene mutations and the underlying mechanisms are complicated and diverse. The causal gene of DMD is the largest one in human that locates in the region of Xp21. 2, encoding dystrophin. Currently there is no effective treatment for DMD patients. The treatment of DMD depends on gene mutation and molecular mechanism study of the disease, which requires reliable disease models such as mdx mouse model. Recently, researchers have increasingly discovered gene therapy strategies for DMD, and the efficacy has been demonstrated in DMD animal models. In addition, induced pluripotent stem cell technology can provide patient-specific cell source, offering a new platform for mechanism and therapy study of DMD.
Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies

Omar Sheikh,Toshifumi Yokota

DOI: https://doi.org/10.1080/13543784.2021.1868434

2021-01-06

Expert Opinion on Investigational Drugs

Abstract:<span>Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder caused by mutations in the dystrophin (DMD) gene. Most patients die from respiratory failure or cardiomyopathy. There are significant unmet needs for treatments for DMD as the standard of care is principally limited to symptom relief through treatments including steroids.This review summarizes safety and efficacy in promising areas of DMD therapeutics – small molecules, stop codon readthrough, gene replacement, and exon skipping – under clinical examination from 2015–2020 as demonstrated in the NIH Clinical Trials and PubMed search engines.Currently, steroids persist as the most accessible medicine for DMD. Stop-codon readthrough, gene replacement, and exon-skipping therapies all aim to restore dystrophin expression. Of these strategies, gene replacement therapy has recently gained momentum while exon-skipping retains great traction. The FDA approval of three exon-skipping antisense oligonucleotides illustrate this regulatory momentum, though the effectiveness and sequence design of eteplirsen remain controversial. Cell-penetrating peptides promise to more efficaciously treat DMD-related cardiomyopathy.The recent success of antisense therapies, however, poses major regulatory challenges. To fully realize the benefits of exon-skipping, including cocktail oligonucleotide-mediated multiple exon-skipping and oligonucleotide drugs for very rare mutations, regulatory challenges need to be addressed in coordination with scientific advances.</span>

pharmacology & pharmacy
Therapeutic developments for Duchenne muscular dystrophy

Ingrid E. C. Verhaart,Annemieke Aartsma-Rus

DOI: https://doi.org/10.1038/s41582-019-0203-3

IF: 38.1

2019-05-30

Nature Reviews Neurology

Abstract:Duchenne muscular dystrophy (DMD) is caused by the lack of functional dystrophin protein. Improvements in patient care and disease management have slowed down disease progression, but current treatments cannot stop the relentless loss of muscle tissue and function, which leads to premature death. Research is ongoing to develop effective therapies for DMD. Gene-addition, exon-skipping, stop codon readthrough and genome-editing therapies can restore the expression of partially functional dystrophin protein, whereas other therapeutic approaches aim to improve muscle function and quality by targeting pathways involved in the pathogenesis of DMD. This Review outlines important developments in these research areas and specifically focuses on new therapies that are in the clinical trial phase or have already been approved.

clinical neurology
Recent developments and industry interest in gene therapy for Duchenne muscular dystrophy

Hidenori Moriyama,Toshifumi Yokota

DOI: https://doi.org/10.1080/14712598.2024.2422998

2024-11-05

Expert Opinion on Biological Therapy

Abstract:KEYWORDS: Duchenne muscular dystrophy (DMD) is a fatal X-linked recessive disease and is known as the most common genetic muscle disease to manifest in childhood. It is caused by mutations in the dystrophin gene, which encodes for the dystrophin protein that is essential for muscle strength and stability. The absence of this protein leads to progressive muscle degeneration and fibrosis. Symptoms typically begin with difficulty walking between the ages of 2 and 5, followed by progressive muscle weakness. By 11 to 13 years of age, walking becomes difficult, and by 20 to 40 years of age, patients may succumb to heart or respiratory failure [ Citation 1 , Citation 2 ]. Four antisense oligonucleotides that restore dystrophin protein through exon skipping have been approved by the FDA. However, their effectiveness is limited, highlighting the urgent need for further therapeutic development. In recent years, gene therapy, including mini-dystrophin/micro-dystrophin gene therapy and clustered regularly interspaced short palindromic repeats (CRISPR)-based approaches has rapidly emerged as a next-generation treatment approach that targets the underlying pathology of DMD and has gained significant attention. Due to the nature of gene editing, this therapy has the potential to provide long-term benefits with a single administration. The field is highly competitive with intense research and development efforts. While an FDA-approved drug has emerged, there have also been reports of serious adverse events and deaths related to the drug administration. This editorial briefly reviews recent developments in gene therapy research for DMD, focusing on both the promising aspects and the challenges, and considers future directions.

medicine, research & experimental,biotechnology & applied microbiology
Therapeutic Strategies for Duchenne Muscular Dystrophy: An Update

Chengmei Sun,Luoan Shen,Zheng Zhang,Xin Xie

DOI: https://doi.org/10.3390/genes11080837

IF: 4.141

2020-07-23

Genes

Abstract:Neuromuscular disorders encompass a heterogeneous group of conditions that impair the function of muscles, motor neurons, peripheral nerves, and neuromuscular junctions. Being the most common and most severe type of muscular dystrophy, Duchenne muscular dystrophy (DMD), is caused by mutations in the X-linked dystrophin gene. Loss of dystrophin protein leads to recurrent myofiber damage, chronic inflammation, progressive fibrosis, and dysfunction of muscle stem cells. Over the last few years, there has been considerable development of diagnosis and therapeutics for DMD, but current treatments do not cure the disease. Here, we review the current status of DMD pathogenesis and therapy, focusing on mutational spectrum, diagnosis tools, clinical trials, and therapeutic approaches including dystrophin restoration, gene therapy, and myogenic cell transplantation. Furthermore, we present the clinical potential of advanced strategies combining gene editing, cell-based therapy with tissue engineering for the treatment of muscular dystrophy.

genetics & heredity
Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing

Britt Hanson,Matthew J.A. Wood,Thomas C. Roberts

DOI: https://doi.org/10.1080/15476286.2021.1874161

2021-01-20

RNA Biology

Abstract:Duchenne muscular dystrophy (DMD) is a currently incurable X-linked neuromuscular disorder, characterized by progressive muscle wasting and premature death, typically as a consequence of cardiac failure. DMD-causing mutations in the dystrophin gene are highly diverse, meaning that the development of a universally-applicable therapy to treat all patients is very challenging. The leading therapeutic strategy for DMD is antisense oligonucleotide-mediated splice modulation, whereby one or more specific exons are excluded from the mature dystrophin mRNA in order to correct the translation reading frame. Indeed, three exon skipping oligonucleotides have received FDA approval for use in DMD patients. Second-generation exon skipping drugs (i.e. peptide-antisense oligonucleotide conjugates) exhibit enhanced potency, and also induce dystrophin restoration in the heart. Similarly, multiple additional antisense oligonucleotide drugs targeting various exons are in clinical development in order to treat a greater proportion of DMD patient mutations. Relatively recent advances in the field of genome engineering (specifically, the development of the CRISPR/Cas system) have provided multiple promising therapeutic approaches for the RNA-directed genetic correction of DMD, including exon excision, exon reframing via the introduction of insertion/deletion mutations, disruption of splice signals to promote exon skipping, and the templated correction of point mutations by seamless homology directed repair or base editing technology. Potential limitations to the clinical translation of the splice modulation and gene editing approaches are discussed, including drug delivery, the importance of uniform dystrophin expression in corrected myofibres, safety issues (e.g. renal toxicity, viral vector immunogenicity, and off-target gene editing), and the high cost of therapy.

biochemistry & molecular biology
Vascular therapy for Duchenne muscular dystrophy (DMD)

Sangharsha Thapa,Shaymaa Elhadidy,Atsushi Asakura

DOI: https://doi.org/10.12703/r/12-3

2023-02-21

Abstract:Duchenne muscular dystrophy (DMD) is a progressive disease characterized by the wasting of the muscles that eventually lead to difficulty moving and, ultimately, premature death from heart and respiratory complications. DMD deficiency is caused by mutations in the gene encoding dystrophin, which prevents skeletal muscle, cardiac muscle, and other cells from producing the functional protein. Located on the cytoplasmic face of the plasma membrane of muscle fibers, dystrophin serves as a component of the dystrophin glycoprotein complex (DGC), mechanically reinforces the sarcolemma, and stabilizes the DGC, preventing it from contraction-mediated muscle degradation. In DMD muscle, dystrophin deficiency leads to progressive fibrosis, myofiber damage, chronic inflammation, and dysfunction of the mitochondria and muscle stem cells. Currently, DMD is incurable, and treatment involves the administration of glucocorticoids in order to delay disease progression. In the presence of developmental delay, proximal weakness, and elevated serum creatine kinase levels, a definitive diagnosis can usually be made after an extensive review of the patient's history and physical examination, as well as confirmation through muscle biopsy or genetic testing. Current standards of care include the use of corticosteroids to prolong ambulation and delay the onset of secondary complications, including respiratory muscle and cardiac functions. However, different studies have been carried out to show the relationship between vascular density and impaired angiogenesis in the pathogenesis of DMD. Several recent studies on DMD management are vascular targeted and focused on ischemia as a culprit for the pathogenesis of DMD. This review critically discusses approaches-such as modulation of nitric oxide (NO) or vascular endothelial growth factor (VEGF)-related pathways-to attenuate the dystrophic phenotype and enhance angiogenesis.
Duchenne muscular dystrophy: pathogenesis and promising therapies

Mengyuan Chang,Yong Cai,Zihui Gao,Xin Chen,Boya Liu,Cheng Zhang,Weiran Yu,Qianqian Cao,Yuntian Shen,Xinlei Yao,Xiaoyang Chen,Hualin Sun

DOI: https://doi.org/10.1007/s00415-023-11796-x

2023-06-02

Journal of Neurology

Abstract:Duchenne muscular dystrophy (DMD) is a severe, progressive, muscle-wasting disease, characterized by progressive deterioration of skeletal muscle that causes rapid loss of mobility. The failure in respiratory and cardiac muscles is the underlying cause of premature death in most patients with DMD. Mutations in the gene encoding dystrophin result in dystrophin deficiency, which is the underlying pathogenesis of DMD. Dystrophin-deficient myocytes are dysfunctional and vulnerable to injury, triggering a series of subsequent pathological changes. In this review, we detail the molecular mechanism of DMD, dystrophin deficiency-induced muscle cell damage (oxidative stress injury, dysregulated calcium homeostasis, and sarcolemma instability) and other cell damage and dysfunction (neuromuscular junction impairment and abnormal differentiation of muscle satellite). We also describe aberrant function of other cells and impaired muscle regeneration due to deterioration of the muscle microenvironment, and dystrophin deficiency-induced multiple organ dysfunction, while summarizing the recent advances in the treatment of DMD.

clinical neurology
Duchenne muscular dystrophy

Dongsheng Duan,Nathalie Goemans,Shin’ichi Takeda,Eugenio Mercuri,Annemieke Aartsma-Rus

DOI: https://doi.org/10.1038/s41572-021-00248-3

IF: 81.5

2021-02-18

Nature Reviews Disease Primers

Abstract:Duchenne muscular dystrophy is a severe, progressive, muscle-wasting disease that leads to difficulties with movement and, eventually, to the need for assisted ventilation and premature death. The disease is caused by mutations in DMD (encoding dystrophin) that abolish the production of dystrophin in muscle. Muscles without dystrophin are more sensitive to damage, resulting in progressive loss of muscle tissue and function, in addition to cardiomyopathy. Recent studies have greatly deepened our understanding of the primary and secondary pathogenetic mechanisms. Guidelines for the multidisciplinary care for Duchenne muscular dystrophy that address obtaining a genetic diagnosis and managing the various aspects of the disease have been established. In addition, a number of therapies that aim to restore the missing dystrophin protein or address secondary pathology have received regulatory approval and many others are in clinical development.

medicine, general & internal
Current Concepts in the Orthopaedic Management of Duchenne Muscular Dystrophy

Matthew Weintraub,Arjun Gupta,Ahmed Khokhar,Michael Vives,Neil Kaushal

DOI: https://doi.org/10.5435/JAAOSGlobal-D-24-00099

2024-07-10

Abstract:Duchenne muscular dystrophy (DMD), a genetic condition marked by progressive muscle degeneration, presents notable orthopaedic challenges, especially scoliosis, which deteriorates patients' quality of life by affecting sitting balance and complicating cardiac and respiratory functions. Current orthopaedic management strategies emphasize early intervention with corticosteroids to delay disease progression and the use of surgical spinal fusion to address severe scoliosis, aiming to enhance sitting balance, alleviate discomfort, and potentially extend patient lifespan. Despite advancements, optimal management requires ongoing research to refine therapeutic approaches, ensuring improved outcomes for patients with DMD. This review synthesizes recent findings on surgical and nonsurgical interventions, underscoring the importance of a multidisciplinary approach tailored to the dynamic needs of patients with DMD.
A review on mechanistic insights into structure and function of dystrophin protein in pathophysiology and therapeutic targeting of Duchenne muscular dystrophy

Abdelbaset Mohamed Elasbali,Waleed Abu Al-Soud,Saleha Anwar,Hassan H Alhassan,Mohd Adnan,Md Imtaiyaz Hassan,Hassan H. Alhassan,Md. Imtaiyaz Hassan

DOI: https://doi.org/10.1016/j.ijbiomac.2024.130544

IF: 8.2

2024-02-01

International Journal of Biological Macromolecules

Abstract:Duchenne Muscular Dystrophy (DMD) is an X-linked recessive genetic disorder characterized by progressive and severe muscle weakening and degeneration. Among the various forms of muscular dystrophy, it stands out as one of the most common and impactful, predominantly affecting boys. The condition arises due to mutations in the dystrophin gene, a key player in maintaining the structure and function of muscle fibers. The manuscript explores the structural features of dystrophin protein and their pivotal roles in DMD. We present an in-depth analysis of promising therapeutic approaches targeting dystrophin and their implications for the therapeutic management of DMD. Several therapies aiming to restore dystrophin protein or address secondary pathology have obtained regulatory approval, and many others are ongoing clinical development. Notably, recent advancements in genetic approaches have demonstrated the potential to restore partially functional dystrophin forms. The review also provides a comprehensive overview of the status of clinical trials for major therapeutic genetic approaches for DMD. In addition, we have summarized the ongoing therapeutic approaches and advanced mechanisms of action for dystrophin restoration and the challenges associated with DMD therapeutics.

polymer science,biochemistry & molecular biology,chemistry, applied
CRISPR-Based Therapeutic Gene Editing for Duchenne Muscular Dystrophy: Advances, Challenges and Perspectives

Guofang Chen,Tingyi Wei,Hui Yang,Guoling Li,Haisen Li

DOI: https://doi.org/10.3390/cells11192964

IF: 6

2022-09-23

Cells

Abstract:Duchenne muscular dystrophy (DMD) is a severe neuromuscular disease arising from loss-of-function mutations in the dystrophin gene and characterized by progressive muscle degeneration, respiratory insufficiency, cardiac failure, and premature death by the age of thirty. Albeit DMD is one of the most common types of fatal genetic diseases, there is no curative treatment for this devastating disorder. In recent years, gene editing via the clustered regularly interspaced short palindromic repeats (CRISPR) system has paved a new path toward correcting pathological mutations at the genetic source, thus enabling the permanent restoration of dystrophin expression and function throughout the musculature. To date, the therapeutic benefits of CRISPR genome-editing systems have been successfully demonstrated in human cells, rodents, canines, and piglets with diverse DMD mutations. Nevertheless, there remain some nonignorable challenges to be solved before the clinical application of CRISPR-based gene therapy. Herein, we provide an overview of therapeutic CRISPR genome-editing systems, summarize recent advancements in their applications in DMD contexts, and discuss several potential obstacles lying ahead of clinical translation.

cell biology
Simulating Adaptive Quests for Increased Player Impact in MMORPGs

E. Tomai,R. Salazar

DOI: https://doi.org/10.1609/aiide.v8i1.12528

2012-10-08

Abstract: In this paper, we present adaptive quests, an extension to the dominant quest model that guides and motivates gameplay in MMORPG shared worlds. The standard model has proven effective, but is significantly incompatible with the desire for player driven change in the world. We present an incremental step to increasing player impact, discuss the problems it creates with the quest model, and show how adaptive quests can help reconcile the two. We present simulation experiments supporting not only that adaptive quests help mitigate those problems, but that they can actually improve them over the standard model.
Corticosteroids for the treatment of Duchenne muscular dystrophy: a safety review

Eszter Czifrus,Daniel J. Berlau

DOI: https://doi.org/10.1080/14740338.2024.2394578

2024-08-30

Expert Opinion on Drug Safety

Abstract:Introduction Duchenne muscular dystrophy (DMD) is an X-linked genetic disorder characterized by progressive muscle degeneration and weakness, caused by mutations in the dystrophin gene. DMD has effects in early age with significantly shortened lifespan and deteriorated quality of life in the second decade, creating an urgent need to develop better therapeutic options. Corticosteroid medication therapy is an integral tool for the management of DMD and several therapeutic options have been recently approved for use.

pharmacology & pharmacy
Toward the correction of muscular dystrophy by gene editing

Eric N. Olson

DOI: https://doi.org/10.1073/pnas.2004840117

IF: 11.1

2021-04-30

Proceedings of the National Academy of Sciences

Abstract:Recent advances in gene editing technologies are enabling the potential correction of devastating monogenic disorders through elimination of underlying genetic mutations. Duchenne muscular dystrophy (DMD) is an especially severe genetic disorder caused by mutations in the gene encoding dystrophin, a membrane-associated protein required for maintenance of muscle structure and function. Patients with DMD succumb to loss of mobility early in life, culminating in premature death from cardiac and respiratory failure. The disease has thus far defied all curative strategies. CRISPR gene editing has provided new opportunities to ameliorate the disease by eliminating DMD mutations and thereby restore dystrophin expression throughout skeletal and cardiac muscle. Proof-of-concept studies in rodents, large mammals, and human cells have validated the potential of this approach, but numerous challenges remain to be addressed, including optimization of gene editing, delivery of gene editing components throughout the musculature, and mitigation of possible immune responses. This paper provides an overview of recent work from our laboratory and others toward the genetic correction of DMD and considers the opportunities and challenges in the path to clinical translation. Lessons learned from these studies will undoubtedly enable further applications of gene editing to numerous other diseases of muscle and other tissues.
New Gene Therapy Strategies for the Deletion of Exon 44 of Dystrophin Gene Based on Gene Editing by TALENs

Ping Li,Yunzhi Pan,Alice S. S. Li,Aijuan Sun,Jia Zhang,H. L. Gao,Pierre Sirois,Kai Li

DOI: https://doi.org/10.4236/ojmc.2013.31001

2013-01-01

Open Journal of Medicinal Chemistry

Abstract:Duchenne Muscular Dystrophy (DMD) is a severe childhood form of muscular dystrophy. Both the severe form and its milder form of Becker Muscular Dystrophy (BMD) are caused by the mutation of dystrophin gene. Different from some other genetic diseases such as hemophilia that can be treated by replacement therapy, there is no effective therapy for muscular dystrophy in conventional medication. Gene editing technology from the recently developed engineered nucleases such as TALENs has been successfully employed in genome modification of a variety of species, and will be applied in gene therapy of selected human diseases. The genetic basis of DMD and BMD indicates that DMD is a good target for gene therapy through returning the reading frame of dystrophin gene. Gene therapy strategies described here may apply to many other genetic diseases. Wider application of TALENs in gene therapy have the potential to dramatically prolong the lifespan of individuals with genetic diseases.
Advancing Biomarker Discovery and Therapeutic Targets in Duchenne Muscular Dystrophy: A Comprehensive Review

Monica Molinaro,Yvan Torrente,Chiara Villa,Andrea Farini

DOI: https://doi.org/10.3390/ijms25010631

IF: 5.6

2024-01-03

International Journal of Molecular Sciences

Abstract:Mounting evidence underscores the intricate interplay between the immune system and skeletal muscles in Duchenne muscular dystrophy (DMD), as well as during regular muscle regeneration. While immune cell infiltration into skeletal muscles stands out as a prominent feature in the disease pathophysiology, a myriad of secondary defects involving metabolic and inflammatory pathways persist, with the key players yet to be fully elucidated. Steroids, currently the sole effective therapy for delaying onset and symptom control, come with adverse side effects, limiting their widespread use. Preliminary evidence spotlighting the distinctive features of T cell profiling in DMD prompts the immuno-characterization of circulating cells. A molecular analysis of their transcriptome and secretome holds the promise of identifying a subpopulation of cells suitable as disease biomarkers. Furthermore, it provides a gateway to unraveling new pathological pathways and pinpointing potential therapeutic targets. Simultaneously, the last decade has witnessed the emergence of novel approaches. The development and equilibrium of both innate and adaptive immune systems are intricately linked to the gut microbiota. Modulating microbiota-derived metabolites could potentially exacerbate muscle damage through immune system activation. Concurrently, genome sequencing has conferred clinical utility for rare disease diagnosis since innovative methodologies have been deployed to interpret the functional consequences of genomic variations. Despite numerous genes falling short as clinical targets for MD, the exploration of Tdark genes holds promise for unearthing novel and uncharted therapeutic insights. In the quest to expedite the translation of fundamental knowledge into clinical applications, the identification of novel biomarkers and disease targets is paramount. This initiative not only advances our understanding but also paves the way for the design of innovative therapeutic strategies, contributing to enhanced care for individuals grappling with these incapacitating diseases.

biochemistry & molecular biology,chemistry, multidisciplinary
Evolving Role of Viltolarsen for Treatment of Duchenne Muscular Dystrophy

LeighAnn Y. Vincik,Alexandra D. Dautel,Abigail A. Staples,Lillian V. Lauck,Catherine J. Armstrong,Jeffery T. Howard,David McGregor,Shahab Ahmadzadeh,Sahar Shekoohi,Alan D. Kaye

DOI: https://doi.org/10.1007/s12325-024-02801-4

2024-02-20

Advances in Therapy

Abstract:Duchenne muscular dystrophy (DMD) is one of the most prevalent X-linked inherited neuromuscular disorders, with an estimated incidence between 1 in 3500 and 5000 live male births. The median life expectancy at birth is around 30 years due to a rapid and severe disease progression. Currently, there is no cure for DMD, and the standard of care is mainly palliative therapy and glucocorticoids to mitigate symptoms and improve quality of life. Recent advances in phosphorodiamidate morpholino antisense oligonucleotide (PMO) technology has proven optimistic in providing a disease-modifying therapy rather than a palliative treatment option through correcting the primary genetic defect of DMD by exon skipping. However, as a result of the high variance in mutations of the dystrophin gene causing DMD, it has been challenging to tailor an effective therapy in most patients. Viltolarsen is effective in 8% of patients and accurately skips exon 53, reestablishing the reading frame and producing a functional form of dystrophin and milder disease phenotype. Results of recently concluded preclinical and clinical trials show significantly increased dystrophin protein expression, no severe adverse effects, and stabilization of motor function. In summary, viltolarsen has provided hope for those working toward giving patients a safe and viable treatment option for managing DMD. This review summarizes an overview of the presentation, pathophysiology, genetics, and current treatment guidelines of DMD, pharmacological profile of viltolarsen, and a summary of the safety and efficacy with additional insights using recent clinical trial data.

pharmacology & pharmacy,medicine, research & experimental
Progress in treatment and newborn screening for Duchenne muscular dystrophy and spinal muscular atrophy

Qing Ke,Zheng-Yan Zhao,Jerry R. Mendell,Mei Baker,Veronica Wiley,Jennifer M. Kwon,Lindsay N. Alfano,Anne M. Connolly,Catherine Jay,Hanna Polari,Emma Ciafaloni,Ming Qi,Robert C. Griggs,Michele A. Gatheridge

DOI: https://doi.org/10.1007/s12519-019-00242-6

2019-01-01

World Journal of Pediatrics

Abstract:Background Advances in treatment for Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA) hold promise for children with these disorders. Accurate genetic diagnosis, early in the disease process, will allow these treatments to be most effective. Newborn screening (NBS) for SMA has been recommended in the United States, and a pilot DMD NBS program is underway in Hangzhou, China. Data sources A PubMed search, limited to the past 5 years, was conducted to identify: (1) therapeutic advancements for DMD/SMA approved by the United States Food and Drug Administration or the European Medicine Agency and (2) The status of NBS for DMD/SMA. Results We review the current state of approved treatments for DMD/SMA. We present recommendations regarding the future of NBS for these diseases, with a focus on the outcomes and challenges of SMA NBS in New York, USA, and the DMD NBS pilot program in Hangzhou, China. Conclusions Approved treatments for DMD and SMA may change the natural history of these diseases. Long-term studies of these treatments are underway. To avoid the known diagnostic delay associated with these disorders and provide optimal effectiveness of these treatments, early identification of patients through NBS will be necessary. Establishing comprehensive follow-up plans for positively identified patients will need to be in place for NBS programs to be successful.
Pharmacological Treatments and Therapeutic Targets in Muscle Dystrophies Generated by Alterations in Dystrophin-Associated Proteins

Alexandra Luna-Angulo,Carlos Landa-Solís,Rosa Elena Escobar-Cedillo,Francisco Javier Estrada-Mena,Laura Sánchez-Chapul,Benjamín Gómez-Díaz,Paul Carrillo-Mora,Hamlet Avilés-Arnaut,Livier Jiménez-Hernández,Dulce Adeí Jiménez-Hernández,Antonio Miranda-Duarte

DOI: https://doi.org/10.3390/medicina60071060

2024-06-27

Abstract:Muscular dystrophies (MDs) are a heterogeneous group of diseases of genetic origin characterized by progressive skeletal muscle degeneration and weakness. There are several types of MDs, varying in terms of age of onset, severity, and pattern of the affected muscles. However, all of them worsen over time, and many patients will eventually lose their ability to walk. In addition to skeletal muscle effects, patients with MDs may present cardiac and respiratory disorders, generating complications that could lead to death. Interdisciplinary management is required to improve the surveillance and quality of life of patients with an MD. At present, pharmacological therapy is only available for Duchene muscular dystrophy (DMD)-the most common type of MD-and is mainly based on the use of corticosteroids. Other MDs caused by alterations in dystrophin-associated proteins (DAPs) are less frequent but represent an important group within these diseases. Pharmacological alternatives with clinical potential in patients with MDs and other proteins associated with dystrophin have been scarcely explored. This review focuses on drugs and molecules that have shown beneficial effects, mainly in experimental models involving alterations in DAPs. The mechanisms associated with the effects leading to promising results regarding the recovery or maintenance of muscle strength and reduction in fibrosis in the less-common MDs (i.e., with respect to DMD) are explored, and other therapeutic targets that could contribute to maintaining the homeostasis of muscle fibers, involving different pathways, such as calcium regulation, hypertrophy, and maintenance of satellite cell function, are also examined. It is possible that some of the drugs explored here could be used to affordably improve the muscular function of patients until a definitive treatment for MDs is developed.

Blastomycosis of the prostate: case report.

Research Progress on Disease Models and Gene Therapy of Duchenne Muscular Dystrophy

Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies

Therapeutic developments for Duchenne muscular dystrophy

Recent developments and industry interest in gene therapy for Duchenne muscular dystrophy

Therapeutic Strategies for Duchenne Muscular Dystrophy: An Update

Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing

Vascular therapy for Duchenne muscular dystrophy (DMD)

Duchenne muscular dystrophy: pathogenesis and promising therapies

Duchenne muscular dystrophy

Current Concepts in the Orthopaedic Management of Duchenne Muscular Dystrophy

A review on mechanistic insights into structure and function of dystrophin protein in pathophysiology and therapeutic targeting of Duchenne muscular dystrophy

CRISPR-Based Therapeutic Gene Editing for Duchenne Muscular Dystrophy: Advances, Challenges and Perspectives

Simulating Adaptive Quests for Increased Player Impact in MMORPGs

Corticosteroids for the treatment of Duchenne muscular dystrophy: a safety review

Toward the correction of muscular dystrophy by gene editing

New Gene Therapy Strategies for the Deletion of Exon 44 of Dystrophin Gene Based on Gene Editing by TALENs

Advancing Biomarker Discovery and Therapeutic Targets in Duchenne Muscular Dystrophy: A Comprehensive Review

Evolving Role of Viltolarsen for Treatment of Duchenne Muscular Dystrophy

Progress in treatment and newborn screening for Duchenne muscular dystrophy and spinal muscular atrophy

Pharmacological Treatments and Therapeutic Targets in Muscle Dystrophies Generated by Alterations in Dystrophin-Associated Proteins